跳转至内容
Merck
CN
  • Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism.

Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism.

Oncogene (2013-07-23)
Y Xu, K L Swartz, K T Siu, M Bhattacharyya, A C Minella
摘要

The mechanisms that coordinate the final mitotic divisions of terminally differentiated bone marrow (BM) erythroid cells with components of their structural and functional maturation program remain largely undefined. We previously identified phenotypes resembling those found in early-stage myelodysplastic syndromes (MDS), including ineffective erythropoiesis, morphologic dysplasia and BM hyper-cellularity, in a knock-in mouse model in which cyclin E mutations were introduced at its two Cdc4 phosphodegrons (CPDs) to ablate Fbw7-dependent ubiquitination and degradation. Here, we have examined the physiologic consequences of cyclin E dysregulation in BM erythroid cells during terminal maturation in vivo. We found that cyclin E protein levels in BM erythroid cells are dynamically regulated in a CPD-dependent manner and that disruption of Fbw7-dependent cyclin E regulation impairs terminal erythroid cell maturation at a discrete stage before enucleation. At this stage of erythroid cell maturation, CPD phosphorylation of cyclin E regulates both cell-cycle arrest and survival. We also found that normal regulation of cyclin E restrains mitochondrial reactive oxygen species (ROS) accumulation and expression of genes that promote mitochondrial biogenesis and oxidative metabolism during terminal erythroid maturation. In the setting of dysregulated cyclin E expression, p53 is activated in BM erythroid cells as part of a DNA damage response-type pathway, which mitigates ineffective erythropoiesis, in contrast to the role of p53 induction in other models of dyserythropoiesis. Finally, cyclin E dysregulation and ROS accumulation induce histone H3 lysine 9 hyper-methylation and disrupt components of the normal terminal erythroid maturation gene expression program. Thus, ubiquitin-proteasome pathway control of G1-to-S-phase progression is intrinsically linked to regulation of metabolism and gene expression in terminally differentiating BM erythroid cells.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
链霉素 硫酸盐, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
β-雌二醇, BioReagent, powder, suitable for cell culture
Sigma-Aldrich
β-雌二醇, ≥98%
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
链霉素 硫酸盐, powder
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
5(6)-羧基二乙酸荧光素 N-琥珀酰亚胺酯, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Supelco
链霉素 溶液, ~1 mg/mL in 1 mM EDTA, analytical standard
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
链霉素 硫酸盐, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
5-Carboxy-fluorescein diacetate N-succinimidyl ester, suitable for fluorescence, ≥95.0% (HPLC)
Sigma-Aldrich
L -抗坏血酸, Vetec, reagent grade, 99%